Ligand-Assisted Vascular Targeting of Polymer Therapeutics

Drug Delivery in Oncology: From Basic Research to Cancer Therapy

Volumn 2, Issue , 2011, Pages 591-625

  Eldar Boock, Anat ^c   Polyak, Dina ^a   Satchi Fainaro, Ronit ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c NONE

Author keywords

Active targeting; Aminopeptidase N; Angiogenesis; Cancer; Hyaluronic acid; Integrin; Polymer therapeutic; Selectin

Indexed keywords

EID: 84862652983     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527634057.ch20     Document Type: Chapter

References (137)

1. Folkman, J. and Kalluri, R. Tumor angiogenesis (2003) in Cancer Medicine (ed. D.W. Kufe), Decker, Hamilton, pp. 161-194.
2. Folkman, J. (2007) Angiogenesis: an organizing principle for drug discovery. Nat. Rev. Drug Discov., 6, 273-286.
3. McDonald, D.M. Angiogenesis and vascular remodeling in inflammation and cancer: biology and architecture of the vasculature (2008) in Angiogenesis: An Integrative Approach from Science to Medicine (eds W.D. Figg and J. Folkman), Springer, New York, pp. 17-35.
4. Matsumoto, T. and Claesson-Welsh, L. (2001) VEGF receptor signal transduction. Sci. STKE, 2001, RE21.
5. Neufeld, G., Cohen, T., Gengrinovitch, S. and Poltorak, Z. (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13, 9-22.
6. Folkman, J. (1971) Tumor angiogenesis therapeutic implications. N. Engl. J. Med., 285, 1182-1186.
7. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 46, 6387-6392.
8. Ferrara, N. and Kerbel, R.S. (2005) Angiogenesis as a therapeutic target. Nature, 438, 967-974.
9. Germano, S. and O'Driscoll, L. (2009) Breast cancer understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. Curr. Cancer Drug Targets, 9, 398-418.
10. Pastorino, F. et al. (2003) Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res., 63, 7400-7409.
11. Stordal, B., Pavlakis, N. and Davey, R. (2007) A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat. Rev., 33, 688-703.
12. Browder, T. et al. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60, 1878-1886.
13. Klement, G. et al. (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest., 105, R15-R24.
14. Man, S. et al. (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res., 62, 2731-2735.
15. Hlatky, L., Hahnfeldt, P. and Folkman, J. (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst., 94, 883-893.
16. Funovics, M., Montet, X., Reynolds, F., Weissleder, R. and Josephson, L. (2005) Nanoparticles for the optical imaging of tumor E-selectin. Neoplasia, 7, 904-911.
17. Landon, L.A. and Deutscher, S.L. (2003) Combinatorial discovery of tumor targeting peptides using phage display. J. Cell. Biochem., 90, 509-517.
18. Ruoslahti, E. (2002) Specialization of tumour vasculature. Nat. Rev. Cancer, 2, 83-90.
19. Ruoslahti, E. (2002) Drug targeting to specific vascular sites. Drug Discov. Today, 7, 1138-1143.
20. Ruoslahti, E. and Rajotte, D. (2000) An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol., 18, 813-827.
21. Ringsdorf, H. (1975) Structure and properties of pharmacologically active polymers. J. Polym. Sci. Symp., 51, 135-153.
22. Hynes, R.O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell, 110, 673-687.
23. Cai, W. and Chen, X. (2006) Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med. Chem., 6, 407-428.
24. Alghisi, G.C., Ponsonnet, L. and Ruegg, C. (2009) The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS ONE, 4, e4449.
25. Hood, J.D. et al. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science, 296, 2404-2407.
26. Borgman, M.P. et al. (2009) Targetable HPMA copolymer- aminohexylgeldanamycin conjugates for prostate cancer therapy. Pharm. Res., 26, 1407-1418.
27. Pike, D.B. and Ghandehari, H. (2010) HPMA copolymer-cyclic RGD conjugates for tumor targeting. Adv. Drug Deliv. Rev., 62, 167-183.
28. Eldar-Boock, A., Miller, K., Sanchis, J., Lupu, R., Vicent, M.J. and Satchi-Fainaro, R. (2010) Integrin assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials, 32, 3862-3874.
29. Polyak, D. et al. (2011) Development of PEGylated doxorubicin-E-[c(RGDfK)2] conjugate for integrin-targeted cancer therapy. Polym. Adv. Technol., 22, 103-113.
30. Kaneshiro, T.L. and Lu, Z.R. (2009) Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials, 30, 5660-5666.
31. Oba, M. et al. (2007) Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins. Bioconjug. Chem., 18, 1415-1423.
32. Xiong, X.B., Ma, Z., Lai, R. and Lavasanifar, A. (2010) The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials, 31, 757-768.
33. Shamay, Y., Paulin, D., Ashkenasy, G. and David, A. (2009) E-selectin binding peptide-polymer-drug conjugates and their selective cytotoxicity against vascular endothelial cells. Biomaterials, 30, 6460-6468.
34. Adar, L., Shamay, Y., Journo, G. and David, A. (2011) Pro-apoptotic peptide-polymer conjugates to induce mitochondrial-dependent cell death. Polym. Adv. Technol., 22, 199-208.
35. Park, K., Lee, M.-Y., Kim, K.S. and Hahn, S.K. (2010) Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials, 31, 5258-5265.
36. Rae, J.M., Creighton, C.J., Meck, J.M., Haddad, B.R. and Johnson, M.D. (2007) MDA-MB-435 cells are derived from M14 melanoma cells - a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat., 104, 13-19.
37. Mitra, S.K. and Schlaepfer, D.D. (2006) Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol., 18, 516-523.
38. Guo, W. and Giancotti, F.G. (2004) Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol., 5, 816-826.
39. Bertozzi, C.R. (1995) Cracking the carbohydrate code for selectin recognition. Chem. Biol., 2, 703-708.
40. Rosen, S.D. and Bertozzi, C.R. (1994) The selectins and their ligands. Curr. Opin. Cell Biol., 6, 663-673.
41. Barthel, S.R., Gavino, J.D., Descheny, L. and Dimitroff, C.J. (2007) Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin. Ther. Targets, 11, 1473-1491.
42. McEver, R.P. (1997) Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj. J., 14, 585-591.
43. Kobayashi, H., Boelte, K.C. and Lin, P.C. (2007) Endothelial cell adhesion molecules and cancer progression. Curr. Med. Chem., 14, 377-386.
44. Kannagi, R., Izawa, M., Koike, T., Miyazaki, K. and Kimura, N. (2004) Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci., 95, 377-384.
45. Laferriere, J., Houle, F. and Huot, J. (2002) Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38. Ann. NY Acad. Sci., 973, 562-572.
46. Ehrhardt, C., Kneuer, C. and Bakowsky, U. (2004) Selectins - an emerging target for drug delivery. Adv. Drug Deliv. Rev., 56, 527-549.
47. Hooper, N.M. (1994) Families of zinc metalloproteases. FEBS Lett., 354, 1-6.
48. Look, A.T., Ashmun, R.A., Shapiro, L.H. and Peiper, S.C. (1989) Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J. Clin. Invest., 83, 1299-1307.
49. Wang, X. et al. (2010) Activity screening and structure-activity relationship of the hit compounds targeting APN/CD13. Fundam. Clin. Pharmacol., 25, 217-228.
50. Lendeckel, U. et al. (2000) Review: the role of membrane peptidases in immune functions. Adv. Exp. Med. Biol., 477, 1-24.
51. Shipp, M.A. and Look, A.T. (1993) Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood, 82, 1052-1070.
52. Luan, Y. and Xu, W. (2007) The structure and main functions of aminopeptidase N. Curr. Med. Chem., 14, 639-647.
53. Bhagwat, S.V. et al. (2001) CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood, 97, 652-659.
54. Petrovic, N. et al. (2007) CD13/APN regulates endothelial invasion and filopodia formation. Blood, 110, 142-150.
55. Pasqualini, R. et al. (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 60, 722-727.
56. Curnis, F. et al. (2002) Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res., 62, 867-874.
57. Isacke, C.M. and Yarwood, H. (2002) The hyaluronan receptor, CD44. Int. J. Biochem. Cell Biol., 34, 718-721.
58. Bajorath, J., Greenfield, B., Munro, S.B., Day, A.J. and Aruffo, A. (1998) Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J. Biol. Chem., 273, 338-343.
59. David, A. (2010) Carbohydrate-based biomedical copolymers for targeted delivery of anticancer drugs. Isr. J. Chem., 50, 204-219.
60. Laurent, T.C. and Fraser, J.R. (1992) Hyaluronan. FASEB J., 6, 2397-2404.
61. Knudson, W. (1996) Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am. J. Pathol., 148, 1721-1726.
62. Camenisch, T.D. and McDonald, J.A. (2000) Hyaluronan: is bigger better. Am. J. Respir. Cell Mol. Biol., 23, 431-433.
63. Lee, J.Y. and Spicer, A.P. (2000) Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr. Opin. Cell Biol., 12, 581-586.
64. Szczepanek, K., Kieda, C. and Cichy, J. (2008) Differential binding of hyaluronan on the surface of tissue-specific endothelial cell lines. Acta Biochim. Pol., 55, 35-42.
65. Eliaz, R.E. and Szoka, F.C. Jr. (2001) Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res., 61, 2592-2601.
66. Peer, D. and Margalit, R. (2004) Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia, 6, 343-353.
67. Peer, D., Park, E.J., Morishita, Y., Carman, C.V. and Shimaoka, M. (2008) Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science, 319, 627-630.
68. Haag, R. and Kratz, F. (2006) Polymer therapeutics concepts and applications. Angew. Chem. Int. Ed. Engl., 45, 1198-1215.
69. Eichhorn, M.E., Strieth, S. and Dellian, M. (2004) Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist. Updat., 7, 125-138.
70. Ingber, D. et al. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature, 348, 555-557.
71. Kudelka, A.P. et al. (1997) A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res., 3, 1501-1505.
72. Kudelka, A.P., Verschraegen, C.F. and Loyer, E. (1998) Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N. Engl. J. Med., 338, 991-992.
73. Bhargava, P. et al. (1999) A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res., 5, 1989-1995.
74. Dezube, B.J. et al. (1998) Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J. Clin. Oncol., 16, 1444-1449.
75. Satchi-Fainaro, R. et al. (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med., 10, 255-261.
76. Mendichi, R., Rizzo, V., Gigli, M. and Schieroni, A.G. (2002) Fractionation and characterization of a conjugate between a polymeric drug-carrier and the antitumor drug camptothecin. Bioconjug. Chem., 13, 1253-1258.
77. Duncan, R., Cable, H.C., Rejmanova, P., Kopecek, J. and Lloyd, J.B. (1984) Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. Biochim. Biophys. Acta, 799, 1-8.
78. Satchi-Fainaro, R. (2002) Targeting tumor vasculature: reality or a dream. J. Drug Target., 10, 529-533.
79. Satchi-Fainaro, R. et al. (2005) Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell, 7, 251-261.
80. Chesler, L. (2007) Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res., 67, 9435-9442.
81. Ofek, P., Miller, K., Eldar-Boock, A., Polyak, D., Segal, E. and Satchi-Fainaro, R. (2010). Special theme issue: polymer therapeutics as novel nanomedicines. Isr. J. Chem., 50, 185-203.
82. Pierschbacher, M.D. and Ruoslahti, E. (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature, 309, 30-33.
83. Liu, S. (2009) Radiolabeled cyclic RGD peptides as integrin alphavbeta3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug. Chem., 20, 2199-2213.
84. Bergelson, J.M., Shepley, M.P., Chan, B.M., Hemler, M.E. and Finberg, R.W. (1992) Identification of the integrin VLA-2 as a receptor for echovirus 1. Science, 255, 1718-1720.
85. Leininger, E. et al. (1991) Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc. Natl. Acad. Sci. USA, 88, 345-349.
86. Pierschbacher, M.D. and Ruoslahti, E. (1987) Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J. Biol. Chem., 262, 17294-17298.
87. Goodman, S.L., Holzemann, G., Sulyok, G.A. and Kessler, H. (2002) Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. J. Med. Chem., 45, 1045-1051.
88. Bogdanowich-Knipp, S.J., Chakrabarti, S., Williams, T.D., Dillman, R.K. and Siahaan, T.J. (1999) Solution stability of linear vs. cyclic RGD peptides. J. Pept. Res., 53, 530-541.
89. Dechantsreiter, M.A. et al. (1999) N-Methylated cyclic RGD peptides as highly active and selective alphaVbeta3 integrin antagonists. J. Med. Chem., 42, 3033-3040.
90. Aumailley, M. et al. (1991) Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett., 291, 50-54.
91. Paolillo, M., Russo, M.A., Serra, M., Colombo, L. and Schinelli, S. (2009) Small molecule integrin antagonists in cancer therapy. Mini. Rev. Med. Chem., 9, 1439-1446.
92. Desgrosellier, J.S. and Cheresh, D.A. (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer, 10, 9-22.
93. Reynolds, A.R. et al. (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med., 15, 392-400.
94. Arap, W., Pasqualini, R. and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, 377-380.
95. Kim, J.W. and Lee, H.S. (2004) Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model. Int. J. Mol. Med., 14, 529-535.
96. Janssen, M. et al. (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother. Radiopharm., 17, 641-646.
97. Janssen, M.L. et al. (2002) Tumor targeting with radiolabeled alphavbeta3 integrin binding peptides in a nude mouse model. Cancer Res., 62, 6146-6151.
98. Janssen, M. et al. (2004) Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother. Radiopharm., 19, 399-404.
99. Wester, H.J. and Kessler, H. (2005) Molecular targeting with peptides or peptide-polymer conjugates: just a question of size. J. Nucl. Med., 46, 1940-1945.
100. Sancey, L. et al. (2009) Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol. Ther., 17, 837-843.
101. Holzbeierlein, J.M., Windsperger, A. and Vielhauer, G. (2010) Hsp90: a drug target. Curr. Oncol. Rep., 12, 95-101.
102. Lattouf, J.B., Srinivasan, R., Pinto, P.A., Linehan, W.M. and Neckers, L. (2006) Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nat. Clin. Pract. Urol., 3, 590-601.
103. Kasuya, Y., Lu, Z.R., Kopeckova, P., Tabibi, S.E. and Kopecek, J. (2002) Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates. Pharm. Res., 19, 115-123.
104. Kaur, G. et al. (2004) Antiangiogenic properties of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin. Cancer Res., 10, 4813-4821.
105. Ryppa, C., Mann-Steinberg, H., Biniossek, M.L., Satchi-Fainaro, R. and Kratz, F. (2009) In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3. Int. J. Pharm., 368, 89-97.
106. Paz-Ares, L. et al. (2008) Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br. J. Cancer, 98, 1608-1613.
107. O'Brien, M.E. et al. (2008) Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J. Thorac. Oncol., 3, 728-734.
108. Langer, C.J. et al. (2008) Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J. Thorac. Oncol., 3, 623-630.
109. Satchi-Fainaro, R., Duncan, R. and Barnes, C.M. (eds) (2006) Polymer Therapeutics for Cancer: Current Status and Future Challenges, Springer, Heidelberg, pp. 1-65.
110. Qu, G., Yao, Z., Zhang, C., Wu, X. and Ping, Q. (2009) PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation. Eur. J. Pharm. Sci., 37, 98-105.
111. Tekade, R.K., Kumar, P.V. and Jain, N.K. (2009) Dendrimers in oncology: an expanding horizon. Chem. Rev., 109, 49-87.
112. Willner, D. et al. (1993) (6-Maleimidocaproyl)hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug. Chem., 4, 521-527.
113. Aagaard, L. and Rossi, J.J. (2007) RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev., 59, 75-86.
114. Ofek, P., Fischer, W., Calderon, M., Haag, R. and Satchi-Fainaro, R. (2010) In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J., 24, 3122-3134.
115. Martens, C.L. et al. (1995) Peptides which bind to E-selectin and block neutrophil adhesion. J. Biol. Chem., 270, 21129-21136.
116. Rihova, B. (1998) Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev., 29, 273-289.
117. Shamay, Y., Paulin, D., Ashkenasy, G. and David, A. (2009) Multivalent display of quinic acid based ligands for targeting E-selectin expressing cells. J. Med. Chem., 52, 5906-5915.
118. Kiessling, L.L. and Pohl, N.L. (1996) Strength in numbers: non-natural polyvalent carbohydrate derivatives. Chem. Biol., 3, 71-77.
119. Roy, R. (1996) Syntheses and some applications of chemically defined multivalent glycoconjugates. Curr. Opin. Struct. Biol., 6, 692-702.
120. Ellerby, H.M. et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med., 5, 1032-1038.
121. Law, B., Quinti, L., Choi, Y., Weissleder, R. and Tung, C.H. (2006) A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity. Mol. Cancer Ther., 5, 1944-1949.
122. Mai, J.C., Mi, Z., Kim, S.H., Ng, B. and Robbins, P.D. (2001) A proapoptotic peptide for the treatment of solid tumors. Cancer Res., 61, 7709-7712.
123. Javadpour, M.M. et al. (1996) De novo antimicrobial peptides with low mammalian cell toxicity. J. Med. Chem., 39, 3107-3113.
124. Wallace, D.C. (2005) Mitochondria and cancer: Warburg addressed. Cold Spring Harb. Symp. Quant. Biol., 70, 363-374.
125. Etrych, T., Jelinkova, M., Rihova, B. and Ulbrich, K. (2001) New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control. Release, 73, 89-102.
126. Jere, D. et al. (2009) Degradable polyethylenimines as DNA and small interfering RNA carriers. Expert Opin. Drug Deliv., 6, 827-834.
127. Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F. and Aigner, A. (2005) RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther., 12, 461-466.
128. Choi, Y.S. et al. (2010) The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials, 31, 1429-1443.
129. Segal, E. et al. (2009) Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS ONE, 4, e5233.
130. Miller, K., Erez, R., Segal, E., Shabat, D. and Satchi-Fainaro, R. (2009) Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew. Chem. Int. Ed. Engl., 48, 2949-2954.
131. Samanna, V., Wei, H., Ego-Osuala, D. and Chellaiah, M.A. (2006) Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp. Cell Res., 312, 2214-2230.
132. Moffatt, S., Wiehle, S. and Cristiano, R.J. (2005) Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13. Hum. Gene Ther., 16, 57-67.
133. Inagaki, Y. et al. (2010) Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis. Biosci. Trends, 4, 56-60.
134. Blaheta, R.A. et al. (2009) Tumor-endothelium cross talk blocks recruitment of neutrophils to endothelial cells: a novel mechanism of endothelial cell anergy. Neoplasia, 11, 1054-1063.
135. Jiang, G. et al. (2008) Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers, 89, 635-642.
136. Mun, G.I. and Boo, Y.C. (2010) Identification of CD44 as a senescence-induced cell adhesion gene responsible for the enhanced monocyte recruitment to senescent endothelial cells. Am. J. Physiol., 298, H2102-H2111.
137. Banquy, X. et al. (2008) Selectins ligand decorated drug carriers for activated endothelial cell targeting. Bioconjug. Chem., 19, 2030-2039.